Amputation and Chemotherapy for Osteosarcoma
Amputation followed by chemotherapy is the standard of care for canine osteosarcoma.
This prospective cohort study enrolls dogs with confirmed osteosarcoma who are receiving standard amputation followed by chemotherapy, monitoring for metastasis through serial chest radiographs and bloodwork. The study follows patients until the onset of metastasis, providing baseline data on disease progression and outcomes under the current standard of care.
Accurate baseline survival and metastasis rates in dogs treated with amputation and chemotherapy will allow comparison with emerging therapies, improving prognostic information and guiding clinical decision‑making.
Evidence level: Állatkísérletes. Állatmodellben vizsgálták.
Related signals
- Systemic Therapy for Osteosarcoma and Ewing Sarcoma
- Potential proteins identified to target in osteosarcoma treatment
- Future Directions in the Treatment of Osteosarcoma
- Is There a Role for Mifamurtide in Nonmetastatic High‑Grade Osteosarcoma? Results From the Italian Sarcoma Group (ISG/OS‑2) and Spanish Sarcoma Group (GEIS‑33) Trials
- The clinical trial landscape of osteosarcoma: integrating trial data, immunotherapeutic trends, and biomarker insights